Summit Partners Public Asset Management LLC Sells 126,122 Shares of RxSight, Inc. (NASDAQ:RXST)

Summit Partners Public Asset Management LLC lessened its holdings in RxSight, Inc. (NASDAQ:RXST - Free Report) by 15.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 687,711 shares of the company's stock after selling 126,122 shares during the period. RxSight accounts for 1.1% of Summit Partners Public Asset Management LLC's holdings, making the stock its 21st biggest position. Summit Partners Public Asset Management LLC owned about 1.71% of RxSight worth $33,994,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in RXST. CWM LLC increased its stake in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company's stock worth $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC grew its holdings in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company's stock valued at $29,000 after buying an additional 521 shares in the last quarter. Quest Partners LLC acquired a new position in RxSight in the 2nd quarter valued at $41,000. Amalgamated Bank increased its position in RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company's stock worth $71,000 after buying an additional 207 shares during the period. Finally, KBC Group NV lifted its holdings in shares of RxSight by 63.6% during the third quarter. KBC Group NV now owns 1,232 shares of the company's stock worth $61,000 after buying an additional 479 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

Insider Buying and Selling

In other RxSight news, Director Shweta Maniar sold 3,782 shares of the business's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the sale, the director now owns 10,902 shares of the company's stock, valued at approximately $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Ilya Goldshleger sold 1,330 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $46.13, for a total value of $61,352.90. Following the completion of the transaction, the insider now owns 42,246 shares of the company's stock, valued at $1,948,807.98. The trade was a 3.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,702 shares of company stock worth $3,059,197 in the last ninety days. 9.36% of the stock is owned by insiders.

RxSight Stock Up 1.0 %

Shares of RXST stock traded up $0.48 during trading hours on Friday, reaching $46.88. The company's stock had a trading volume of 254,146 shares, compared to its average volume of 486,556. RxSight, Inc. has a fifty-two week low of $28.88 and a fifty-two week high of $66.54. The firm's 50 day simple moving average is $48.70 and its 200-day simple moving average is $52.39. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -56.48 and a beta of 1.19.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Oppenheimer decreased their price target on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Jefferies Financial Group started coverage on RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 price target for the company. Stifel Nicolaus lowered their price objective on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Finally, Wells Fargo & Company cut their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.